19 June 2013
Keywords: bbg, new, cancer, drug, enters, trials, phase
Article | 22 June 1992
A Phase I/II clinical trial of British Bio-technology Group's novel
broad spectrum matrix metalloproteinase inhibitor, BB-94, has now begun
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 June 1992
15 June 1992
© 2013 thepharmaletter.com